testolactone has been researched along with Fibrous Dysplasia, Polyostotic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feuillan, PP | 2 |
| Cutler, GB; Feuillan, PP; Jones, J | 1 |
| Cutler, GB; Feuillan, P; Leschek, EW; Merke, D | 1 |
| Cutler, GB; Feuillan, PP; Jones, J; Manasco, PK; Oerter, KE | 1 |
| Hauffa, BP; Havers, W; Stolecke, H | 1 |
| Barnes, K; Cutler, GB; Dwyer, A; Feuillan, PP; Foster, CM; Hench, KD; Loriaux, DL; Malley, JD; Pescovitz, OH; Shawker, T | 1 |
| Barnes, KM; Cassorla, FG; Comite, F; Cutler, GB; Feuillan, PP; Foster, CM; Kenigsberg, D; Laue, L; Pescovitz, OH; Ross, JL | 1 |
3 review(s) available for testolactone and Fibrous Dysplasia, Polyostotic
| Article | Year |
|---|---|
McCune-Albright syndrome.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Female; Fibrous Dysplasia, Polyostotic; Humans; Male; Puberty, Precocious; Testolactone | 1997 |
Use of aromatase inhibitors in precocious puberty.
Topics: Adrenal Hyperplasia, Congenital; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estrogens; Female; Fibrous Dysplasia, Polyostotic; Humans; Male; Puberty, Precocious; Testolactone | 1999 |
Pubertal growth: physiology and pathophysiology.
Topics: Aging; Body Height; Dose-Response Relationship, Drug; Estradiol; Female; Fibrous Dysplasia, Polyostotic; Gonadotropin-Releasing Hormone; Gonadotropins; Growth; Growth Hormone; Humans; Insulin-Like Growth Factor I; Male; Puberty; Puberty, Delayed; Puberty, Precocious; Sex Characteristics; Testolactone; Thyroid Hormones; Turner Syndrome; Ulna | 1986 |
5 other study(ies) available for testolactone and Fibrous Dysplasia, Polyostotic
| Article | Year |
|---|---|
McCune-Albright syndrome.
Topics: Adolescent; Calcitriol; Diagnosis, Differential; Female; Fibrous Dysplasia, Polyostotic; Humans; Ketoconazole; Leuprolide; Male; Medroxyprogesterone Acetate; Octreotide; Ovariectomy; Propylthiouracil; Puberty, Precocious; Spironolactone; Testolactone; Thyroid Diseases | 1994 |
Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
Topics: Age Determination by Skeleton; Androstenedione; Body Height; Bone Development; Child; Child, Preschool; Estradiol; Female; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Menstruation; Puberty; Puberty, Precocious; Testolactone; Testosterone | 1993 |
Luteinizing hormone-releasing hormone (LHRH)-independent precocious puberty unresponsive to LHRH agonist therapy in two girls lacking features of the McCune-Albright syndrome.
Topics: Child Development; Child, Preschool; Drug Resistance; Female; Fibrous Dysplasia, Polyostotic; Gonadotropin-Releasing Hormone; Humans; Puberty, Precocious; Testolactone | 1991 |
Short-term effects of testolactone compared to other treatment modalities on longitudinal growth and ovarian activity in a girl with McCune-Albright syndrome.
Topics: Androgen Antagonists; Body Height; Bone Development; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Follow-Up Studies; Humans; Infant; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovarian Cysts; Ovarian Function Tests; Spironolactone; Testolactone | 1987 |
Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
Topics: Aromatase Inhibitors; Bone Development; Child, Preschool; Estradiol; Estrone; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Growth; Humans; Infant; Luteinizing Hormone; Menstruation; Ovary; Puberty, Precocious; Sexual Maturation; Testolactone | 1986 |